Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine

Zuzana Berrong, Shamim Ahmad, Rasha Abu Eid, Abdeljabar El-Andaloussi , Tanusree Sen, Ross Stewart, Scott A. Hammond, Rajeev Shrimali, Mikayel Mkrtichyan, Samir N Khleif

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Original languageEnglish
Title of host publicationJournal for ImmunoTherapy of Cancer
Subtitle of host publicationAbstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)
PublisherBioMed Central
Pages226
Number of pages1
Volume2
EditionSuppl 3
DOIs
Publication statusPublished - 6 Nov 2014
EventSociety for Immunotherapy of Cancer 29th Annual Meeting - National Harbor, Maryland, United States
Duration: 6 Nov 20149 Nov 2014

Conference

ConferenceSociety for Immunotherapy of Cancer 29th Annual Meeting
Abbreviated titleSITC
CountryUnited States
CityMaryland
Period6/11/149/11/14

Cite this

Berrong, Z., Ahmad, S., Abu Eid, R., El-Andaloussi , A., Sen, T., Stewart, R., Hammond, S. A., Shrimali, R., Mkrtichyan, M., & Khleif, S. N. (2014). Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine. In Journal for ImmunoTherapy of Cancer : Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC) (Suppl 3 ed., Vol. 2, pp. 226). BioMed Central. https://doi.org/10.1186/2051-1426-2-S3-P226